CG Oncology
CGON
233 hedge funds and large institutions have $5.93B invested in CG Oncology in 2026 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 81 increasing their positions, 61 reducing their positions, and 23 closing their positions.
183% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 23
144% more call options, than puts
Call options by funds: $213M | Put options by funds: $87.2M
73% more capital invested
Capital invested by funds: $3.43B → $5.93B (+$2.5B)
33% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 61
19% more funds holding
Funds holding: 195 → 233 (+38)
1.94% more ownership
Funds ownership: 102.44% → 104.38% (+1.9%)
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$357M |
| 2 |
RI
RTW Investments
New York
|
+$282M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$56.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$37.7M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$26.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
-$81.6M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$53.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$50.2M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$39.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$35.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
251
GSA Capital Partners
London,
United Kingdom
| – | -$207K | -4,977 | Closed |
|
|
BG
252
Bellevue Group
Kuesnacht,
Switzerland
| – | -$129K | -3,095 | Closed |
|
|
AB
253
Amalgamated Bank
New York
| – | -$73K | -1,756 | Closed |
|
254
Daiwa Securities Group
Tokyo,
Japan
| – | -$10K | -239 | Closed |
|
|
CCA
255
Cygnus Capital Advisors
Atlanta,
Georgia
| – | -$9 | -221 | Closed |
|
|
BWA
256
Basecamp Wealth Advisors
Bellevue,
Washington
| – | -$747 | -18 | Closed |
|
CGON Hedge Fund Activity: Q1 2026 in Review
233 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q1 2026, worth a combined $5.93B — up 73% from $3.43B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new CGON positions and 23 closed out — a net gain of 42 holders — while 81 added to existing stakes and 61 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $357M. The largest seller was Seven Fleet Capital Management, cutting an estimated $81.6M.
- 233 institutional investors held CG Oncology (CGON) as of Q1 2026, up from 195 in Q4 2025.
- Funds reported $5.93B of CG Oncology stock for Q1 2026, up 73% quarter-over-quarter.
- 65 funds opened new CG Oncology positions in Q1 2026 and 23 closed out, a net change of +42 holders.
- The largest CG Oncology buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $357M added.
- The largest CG Oncology seller in Q1 2026 was Seven Fleet Capital Management, an estimated $81.6M sold.
Based on aggregated 13F filings for Q1 2026.